SCHEDULE: RA Capital Discloses 6.5% Stake in Altimmune

RA Capital Management and its principals have reported a 6.5% beneficial ownership stake in Altimmune, Inc. following a recent equity offering.

Summary

• RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13G reporting beneficial ownership of 13,000,000 shares of Altimmune, Inc. common stock.
• The reported stake represents 6.5% of the company's outstanding common stock.
• The holdings consist of 6,500,000 shares of common stock and warrants exercisable for an additional 6,500,000 shares.
• The filing confirms the acquisition of these securities in connection with the company's public offering that closed on April 24, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive development, as it confirms institutional interest and participation in the company's recent capital raise without indicating any activist intent.

Positives

• Significant institutional backing from a specialized healthcare investment firm.
• The investment indicates confidence in the company's recent capital raise and strategic direction.

Negatives

• The investment includes warrants, which may lead to future dilution if exercised.

Risks

• Market volatility associated with biotechnology equity offerings.
• Potential for future dilution of existing shareholders upon the exercise of the 6,500,000 common warrants.

Future Outlook

The reporting persons state that the securities were acquired for investment purposes and not for the purpose of changing or influencing the control of the issuer.

Management Comments

• The reporting persons expressly disclaim status as a group for purposes of this Schedule 13G.
• The reporting persons certify that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that RA Capital is a prominent life sciences investor; their participation in Altimmune's recent public offering is a standard institutional validation signal for biotech companies seeking to bolster their balance sheets for clinical development.

Comparison to Industry Standards

• The filing follows standard regulatory requirements for institutional investors exceeding the 5% ownership threshold.
• The use of a Joint Filing Agreement is common practice for affiliated investment entities to streamline SEC reporting.

Stakeholder Impact

• Shareholders may view the entry of a major healthcare-focused fund as a vote of confidence in the company's pipeline.
• Existing shareholders should note the potential for dilution from the 6.5 million warrants held by the reporting entity.

Next Steps

• Potential future amendments to the Schedule 13G if there are material changes in the percentage of ownership.

Key Dates

Keywords

Altimmune, RA Capital, Schedule 13G, Biotechnology, Institutional Ownership, Equity Offering